You are viewing the site in preview mode

Skip to main content

Advertisement

Table 3 Relation of in vitro predicted susceptibility to reduction in P. aeruginosa bacterial burden at END of PEx therapies

From: Reduction in Pseudomonas aeruginosa sputum density during a cystic fibrosis pulmonary exacerbation does not predict clinical response

Factor ALL MUC NON
Value OR (95% CI) Value OR (95% CI) Value OR (95% CI) Value OR (95% CI) Value OR (95% CI) Value OR (95% CI)
1-log reduction 2-log reduction 1-log reduction 2-log reduction 1-log reduction 2-log reduction
All Isolates S to β-lactam vs not 59/91 vs 8/27 2.18 (CI 1.2-3.99) p = 0.002 48/91 vs 6/27 2.38 (1.14-4.94) p < 0.01 63/79 vs 10/20 1.59 (1.02-2.51), p = 0.01 48/79 vs 7/20, 1.73 (1.0-3.23) p = 0.05 55/81 vs 8/27 2.29 (1.26-4.18), p < 0.001 44/81 vs 6/27 2.44 (1.17-5.09), p = 0.004
All isolates S to TOB vs not 32/53 vs 35/65 1.12 (0.82-1.53), p = 0.56 29/55 vs 25/65 1.37 (0.92-2.03), p = 0.14 34/46 vs 39/53 1.0 (0.79-1.27), p = 1 28/46 vs 27/53 1.19 (0.84-1.69), p = 0.41 28/45 vs 35/63 1.12 (0.82-1.54), p = 0.56 25/45 vs 25/63 1.4 (0.94-2.1), p = 0.12
Regimen with 2 vs ≤1 MUC agent* 47/73 vs 12/25 1.34 (0.87-2.08), p = 0.16 39/73 vs 9/25 1.48 (0.85-2.61), p = 0.16 57/74 vs 16/25 1.2 (0.88-1.66), p = 0.29 45/74 vs 10/25 1.52 (0.91-2.54), p = 0.1 N/A N/A
Regimen with 2 vs ≤1 NON agent* 29/41 vs 33/67 1.43 (1.05-1.96), p = 0.04 26/41 vs 24/67 1.77 (CI 1.19-2.63), p = 0.006 N/A N/A 30/41 vs 33/67 1.49 (1.09-2.02), p = 0.02 26/41 vs 24/67 1.77 (1.19-2.63), p = 0.006
MDR at PEx* vs not N/A N/A 2/5 vs 59/77 0.52 (0.18-1.54), p = 0.1 1/5 vs 46/77 0.33 (0.06-1.95) p = 0.15 19/41 vs 33/47 0.66 (0.45-0.96), p = 0.03 14/41 vs 27/47 0.6 (0.36-0.97), p = 0.03
MDR in prior year* vs not N/A N/A 13/18 vs 47/63 0.96 (0.96-0.7-1.3), p = 1 11/18 vs 36/63 1.06 (0.7-1.63), p = 0.8 22/51 vs 30/36, 0.52 (0.36-0.73), p < 0.001 17/51 vs 24/36 0.5 (0.32-0.78), p = 0.003
PDR at PEx* vs not N/A N/A 0/1 vs 61/81 n/a p = 0.21 0/1 vs 46/79 n/a p = 0.4 5/13 vs 47/75 0.61 (0.3-1.29),p = 0.13 4/13 vs 37/75 0.62 (0.27-1.45), p = 0.24
PDR in prior year* vs not N/A N/A 0/1 vs 59/79 n/a p = 0.26 0/1 vs 46/79 n/a p = 0.43 8/22 vs 43/65 0.55 (0.31-0.98), p = 0.02 7/22 vs 34/65 0.61 (0.32-1.17), p = 0.14
  1. *In these events, bacteriologic response of P. aeruginosa was evaluated specifically against the morphotype type that susceptibility was being evaluated.
  2. S = sensitive as defined by CLSI criteria. TOB = tobramycin. MUC = mucoid isolate, NON = non-mucoid isolate. PEx = pulmonary exacerbation. OR = Odds ratio, CI = confidence interval. N/A = not applicable.
  3. MDR/PDR at event = Presence of an MDR/PDR isolate at admission sputum sample of the PEx being evaluated.
  4. MDR/PDR in prior year = Presence of an MDR/PDR isolate at any time-point in the one year prior to the PEx event being evaluated.